

TRADE/2171 - Meeting with

Art.4(1)(b)

Art.4(1)(b)

MSD, a biopharmaceutical company, subsidiary of Merck & Co

Meeting date and place

Meeting held on 22/02/2022 08:00

Participating organisation(s) representative(s)

Main issues discussed

The meeting was requested by MSD to discuss the ongoing revision of the EU pharmaceutical legislation, as announced in the EU Pharmaceutical Strategy of 2020. As a biopharmaceutical company, involved in research, MSD sees the revision of the EU's legislation in this area as an opportunity to improve the regulatory framework for the innovative companies. However, they also see the risk that certain incentives currently available to the industry, including with regard to orphan and paediatric medicines, could be reduced or made conditional. The preparation of the assessment is still in early stages and the role of DG TRADE in the Commission's interservice context was discussed.

Directorate or unit

TRADE.B.3

Internal participants

Art.4(1)(b) TRADE B/3 Art.4(1)(b) @ec.europa.eu Notetaker, Participant

Author(s) of minutes

Art.4(1)(b)

Validator and validation date

Art.4(1)(b)